A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52 Week Study to Evaluate the Efficacy and Safety of LY3454738 in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52 Week Study to Evaluate the Efficacy and Safety of LY3454738 in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).
Inclusion Criteria:
ISA specific:
Have moderate-to-severe AD, defined as meeting all of the following criteria, at the first dosing visit:
Have applied at least 1 emollient every day for at least 2 weeks before the day of the first dose of study intervention in this ISA and agree to daily use of at least 1 emollient continuously throughout the study.
Exclusion Criteria:
ISA specific:
Obihiro-shi, Hokkaido 080-0013, Japan
Chuo-ku, Tokyo 103-0025, Japan
Cuauhtémoc, Ciudad de México, Mexico City 06100, Mexico
Lodz, Łódź Voivodeship 90-436, Poland
Bupyeong-gu, Incheon-gwangyeoksi [Incheon] 21431, South Korea
Dongjak-gu, Seoul-teukbyeolsi [Seoul] 06973, South Korea
Kaohsiung Niao Sung Dist, Kaohsiung 83301, Taiwan
Taipei City, Taipei 114, Taiwan